Skip to main content

Advertisement

Table 4 Incremental cost-effectiveness ratio (per patient)

From: Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

  FOLFOX4 Sorafenib Incremental
Discounted
 Drug costs US$ 6972 US$ 12,289 − US$ 5317
 General ward costs US$ 145 US$ 0 US$ 145
 AE costs US$ 69 US$ 4 US$ 64
 Tests US$ 1242 US$ 504 US$ 738
 Total costs US$ 8428 US$ 12,798 − US$ 4371
 QALY 0.42 0.38 0.034
    FOLFOX4 dominance